This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.94% higher to $468.09 Monday, on what proved to be an all-around mixed ...

正如预期的那样，今年制药公司对并购仍有兴趣，但相较于大型并购，制药公司更倾向于小额交易。迄今为止宣布的最大额的一笔交易是Novo Holdings拟以165亿美元收购CDMO公司Catalent。

Stifel raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $494 from $490 and keeps a Hold rating on the shares. With shares up ...

Jefferies has upgraded Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), citing the company’s robust cystic fibrosis base business ...

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of ...

Jefferies分析师预测，Vertex的管线产品，特别是二期LSR疼痛和三期DPN疼痛治疗，将从2026年开始贡献50亿美元的新业务。正在进行的DPN疼痛三期试验尤为值得关注，预计将进入FDA审查和市场推出阶段。

Vertex Pharmaceuticals (VRTX) closed at $468.09 in the latest trading session, marking a +0.94% move from the prior day.

"Patients will die as a result of this decision," said Gayle Pledger of the Right to Breathe advocacy campaign.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective hoisted by equities research analysts at Stifel Nicolaus from $490.00 to $494.00 in a report released on Monday,Benzinga ...